Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 67Carcinoma, Non-Small-Cell Lung 45Lung Neoplasms 42Lymphoma 36Prostatic Neoplasms 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Ovarian Neoplasms 27Uterine Cervical Neoplasms 23Central Nervous System Neoplasms 22Neoplasm Metastasis 21Fallopian Tube Neoplasms 21Colorectal Neoplasms 21Leukemia 20Neuroblastoma 17Head and Neck Neoplasms 17Rectal Neoplasms 16Brain Neoplasms 16Adenocarcinoma of Lung 16Sarcoma 15Squamous Cell Carcinoma of Head and Neck 14Glioblastoma 14Colonic Neoplasms 14Burkitt Lymphoma 14Leukemia, Myeloid, Acute 13HIV Infections 13Urinary Bladder Neoplasms 12Lymphoma, Large B-Cell, Diffuse 12Multiple Myeloma 11Hodgkin Disease 11Astrocytoma 11

Interventions

tremelimumab 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Has results × Advanced Rare Tumours × Clear all
NCT02879162 2025-03-07

Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Canadian Cancer Trials Group

Phase 2 Completed
140 enrolled 9 charts

Advanced Rare Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡